# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

**Basil Rapoport** 

Application No. 08/482,402

Group Art Unit: 1806

Filed: **June 7, 1995** 

Examiner: S. Ungar

DISEASE ASSOCIATED HUMAN AUTOANTIBODIES

SPECIFIC FOR HUMAN THYROID PEROXIDASE

Attorney Docket No: 102105.151CIPDIV3

Assistant Commissioner of Patents Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97(c) and 1.98, Applicants bring to the attention of the Examiner the documents listed on the six attached PTO-1449 forms.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that the listed documents do not constitute prior art under United States law, Applicants reserve the right to present to the Patent Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

A copy of the documents listed on the six attached PTO-1449 forms is submitted herewith.

# U.S. Application No. 08/482,402 Information Disclosure Statement

Applicants respectfully request that the Examiner initial and return a copy of the six enclosed PTO-1449 forms with the next communication from the Patent Office.

This Information Disclosure Statement is being filed after the first Office Action on the merits, but before a final Office Action and before a notice of allowance. Accordingly, the Commissioner is hereby authorized to charge the fee of \$240 to Deposit Account No. 08-0219, and to make any other necessary charges or credit any overpayments to Deposit Account No. 08-0219. A duplicate copy of this paper is enclosed.

Respectfully submitted

Henry N. W

Registration No. 32,073

Date: 21 JULY 1998

HALE and DORR LLP

1455 Pennsylvania Avenue, NW

Washington, DC 20004

(202) 942-8400

/netuser19/michl/NICHOLS/151/div3/IDS-1.wpf

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE												102105.151CIPDIV3 SERIAL NO. 08/482,402				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT												APPLICANT Basil Rapoport				
(Use several sheets if necessary) (37 CRF 1.98(b))								essa	iry)		FILING DATE June 7, 1995					
									U	S. PAT	ENT	DOCUMENTS				
EXAMINER INITIALS			PATENT NUMBER							DATE PATENTE		PATENTEE	CLASS	SUBCLASS	FILING DAT	
		4	3	7	e	5 1	1	0	0:	3/08/83	Da	vid et al			<u> </u>	
		4	0	9	8	8	7	6	04	4/04/78	Pia	sio et al				
		_	<u> </u>		L	<u></u>	_				<u></u>		<u> </u>			
· · · · · · · · · · · · · · · · · · ·		_		- OH		GN	<b>P</b> A	\IE	T .			SHED PATENT	APPLICA	ATION	-	
	ļ	D	ocı	JME	NT	NU.	мве	R	PL			COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
	_		Γ.	r	Г.	_		_		_				YES	NO	
		9	3	2	1	1			$\overline{}$		EPC			<u> </u>	ļ	
	$\dashv$	9	_	0	3	_	7 4		$\mathbf{r}$	3.03.93 3.02.93		r/wo		<del> </del>		-
		9		0	2	_	6		_	.02.91	_	r/wo		<del> </del>		
														<b>-</b>		
OTHER	DOC	CU	ME	NT	S (	(inc	lud	ing	) A	uthor, 1	litie,	Date, Relevan	t pages, l	Place of Pu	blication	n)
		Finke et al, Journal of Clinical Endocrinology and Metabolism,								<del></del> -						
	Vol. 71(1), pages 53-59, 1990.															
		1	Po	otoc	nj	ak e	et a	1, 5	Sci	ence, V	ol. 2	15, pages 1637	'-1639, 1 <u>9</u>	982.		
Portolano et al, Biochemical and Biophysical Research Commo						communicat	ions,	<u></u>								
					Vol. 179(1), pages 372-377, 1991.											
			Ва	ing	a e	et a	, J	our	na	of End	ocrir	nology, Vol. 124	(Supp.),			
	$\perp$			Al	ost	rac	t No	o. 1	196	6, 1990.						
İ		$\perp$	Ev	vins	e	t al,	Jo	urr	nal	of Endo	crin	ology, Vol. 124	(Supp.),	· · · · · · · · · · · · · · · · · · ·		
				At	ost	rac	No	o. 8	36,	1990.						
CAMINER											C	PATE CONSIDERED	)			
KAMINER: II	nitia nclu	l ci	tati	ion py (	co of	nsic this	dere	ed.	D wit	raw line h next c	thro	ough citation if nunication to app	ot in conf	ormance ar	ad not	

 $I \rightarrow$ 

(Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

1 ;

APPLICANT **Basil Rapoport** 

June 7, 1995

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE

ATTY DOCKET NO. 102105.151CIPDIV3

GROUP 1806

SERIAL NO.

08/482,402

(Use several sheets if necessary) (37 CRF 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

	Ludgate et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 68(6), pages 1091-1095, 1989.
	Kimura et ai, <i>FEBS Letters</i> , Vol. 250(2), pages 377-380, 1989.
	Wahl et al, The Journal of Nuclear Medicine, Vol. 24, pages 316-325, 1983.
	Ruf et al, Clincal Chemistry, Vol. 34(11), pages 2231-2234, 1988.
	Kaufman et al, Molecular and Cellular Endocrinology,
	Vol. 78, pages 107-114, 1991.
	Burgess et al, The Journal of Cell Biology, Vol. 111, pages 2129-2138, 1990.
	Tao et al, The Journal of Immunology, Vol. 143(8), pages 2395-2601, 1989.
	Gillies et al, Hum. Antibod. Hybridomas, Vol. 1(1), pages 47-54, 1990.
	Lazar et al, Molecular and Cellular Biology, Vol. 8(3), pages 1247-1252, 1988.
	Kendler et al, Clinical Endocrinology, Vol. 33, pages 751-760, 1990.
	Foti et al, Biochemical and Biophysical Research Communications,
	Vol. 168(1), pages 281-287, 1990.
EXAMINER	DATE CONSIDERED

# FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

# PATENT AND TRADEMARK OF INFORMATION DISCLOSURE

 $I_{-1}$ 

STATEMENT BY APPLICANT

(Use several sheets if necessary) (37 CRF 1.98(b))

ATTY DOCKET NO. 102105.151CIPDIV3

**SERIAL NO.** 08/482,402

APPLICANT

Basil Rapoport

FILING DATE June 7, 1995

**GROUP** 1806

# OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

	Kaufman et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 70(3), pages 724-728, 1990.
	Magnusson et al, <i>FEBS Letters</i> , Vol. 208(2), pages 391-396, 1986.
	Magnusson et al, The Journal of Biological Chemistry,
	Vol. 262(29), pages 13885-13888, 1987.
	Libert et al, The EMBO Journal, Vol. 6(13), pages 4193-4196, 1987.
	Magnusson et al, <i>Molecular Endocrinology</i> , Vol. 1(11), pages 856-861, 1987.
	Kimura et al, Proc. Natl. Acad, Sci. USA, Vol. 84, pages 5555-5559, 1987.
	Adler et al, Analytical Biochemistry, Vol. 148, pages 320-327 (1985).
	Bogner et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 59(4), pages 734-738, 1984.
	Clark et al, Enzyme-Immunoassay, Chapter 8, pages 167-170 and 191-194.
	Czarnocka et al, <i>FEBS Letters</i> , Vol. 190(1), pages 147-152, 1985.
ł	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary) (37 CRF 1.98(b))

ATTY DOCKET NO. 102105.151CIPDIV3

SERIAL NO. 08/482,402

APPLICANT

**Basil Rapoport** 

FILING DATE June 7, 1995 GROUP 1806

# OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

	( Publication)
	Doble et al, Immunology, Vol. 64, pages 23-29, 1988.
	Elisel et al, Autoimmunity, Voi. 8. pages 65-70, 1990.
	2.001 of al, Matematiky, 901. 8. pages 65-70, 1990.
	Hirayu et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 64(3), pages 578-584, 1987.
	Finke et al, Progress in Thyroid Research, pages 437-439, 1991.
	Finke et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 73(4), pages 919-921, 1991.
	Jansson et al, Clin exp. Immunol., Vol. 63, pages 80-86, 1986.
	Kaufman et al, The Journal of Clinical Investigation,
	Vol. 84, pages 394-403, 1989.
	Kohno et al, Clin exp. Immunol., Vol. 65, pages 534-541, 1986.
	Kohno et al, Journal of Clinical Endocrinology and Metabolism,
	Vol. 67(5), pages 899-907, 1988.
ĺ	
XAMINER	
overvieti i a PP 1. i	DATE CONSIDERED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CRF 1.98(b))

ATTY DOCKET NO. 102105.151 CIPDIV3

APPLICANT

Basil Rapoport

FILING DATE

June 7, 1995

1806

# OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

	1 L	Libert et al, Journal of Clinical Endocrinology and Metabolism,
		Vol. 73(4), pages 857-860, 1991.
		Mariotti et al, Journal of Clinical Endocrinology and Metabolism,
	l. [	Vol. 65(5), pages 987-993, 1987.
		Nilsson et al, Molecular and Cellular Endocrinology,
		Vol. 53, pages 177-186, 1987.
		Ohtaki et al, Journal of Clinical Endocrinology and Metabolism,
		Vol. 63(3), pages 570-576, 1986.
		Portmann et al, Journal of Clinical Endocrinology and Metabolism,
		Vol. 61(5), pages 1001-1003, 1985.
		Portmann et al, Journal of Clinical Investigation,
		Vol. 81, pages 1217-1224, 1988.
		Ruf et al, <i>Endocrinology</i> , Vol. 125(3), pages 1211-1218, 1989.
		Sanger et al, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 74(12), pages 5463-5467, 1977.
		Van Regenmortel et al, Immunology Letters, Vol. 17, pages 95-108, 1988.
		Yokoyama et al, Journal of Clinical Endocrinology and Metabolism,
		Vol. 68(4), pages 766-773, 1989.
· · · · · · · · · · · · · · · · · · ·		
EXAMINER		DATE CONSIDERED
<del></del>	····	

#### Sheet 1 of 6 ATTY DOCKET NO. 102105.151CIPDIV3 SERIAL NO. FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE 08/482,402 (Modified) PATENT AND TRADEMARK OFFICE **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Basil Rapoport FILING DATE GROUP (Use several sheets if necessary) (37 CRF 1.98(b)) June 7, 1995 1806 **U.S. PATENT DOCUMENTS EXAMINER** ISSUE FILING DATE INITIALS SUBCLASS IF APPROPRIATE DATE **CLASS** PATENT **PATENTEE** NUMBER 0 03/08/83 David et al 0 9 8 8 7 6 04/04/78 | Piasio et al FOREIGN PATENT OR PUBLISHED PATENT APPLICATION PUBLICATION **COUNTRY OR** TRANSLATION DOCUMENT NUMBER DATE CLASS SUBCLASS **PATENT OFFICE** YES NO 9 10.05.90 EPO 0 18.03.93 PCT/WO 6 18.02.93 9 0 PCT/WO 0 6 1 21.02.91 0 2 PCT/WO OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication) Finke et al, Journal of Clinical Endocrinology and Metabolism, Su Vol. 71(1), pages 53-59, 1990. Potocnjak et al, Science, Vol. 215, pages 1637-1639, 1982. Portolano et al, Biochemical and Biophysical Research Communications, Vol. 179(1), pages 372-377, 1991. Banga et al, Journal of Endocrinology, Vol. 124 (Supp.), Abstract No. 196, 1990. Ewins et al, Journal of Endocrinology, Vol. 124 (Supp.),

**EXAMINER:** Initial Citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

95/

Abstract No. 86, 1990.

**EXAMINER** 

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

APPLICANT

SERIAL NO. 08/482,402

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE

June 7, 1995

**Basil Rapoport** 

ATTY DOCKET NO. 102105.151CIPDIV3

**GROUP** 1806

(Use several sheets if necessary)

(37 CRF 1.98(b))

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

IPE CUI	Ludgate et al, Journal of Clinical Endocrinology and Metabolism,
, , , , , , , , , , , , , , , , , , ,	Vol. 68(6), pages 1091-1095, 1989.
JUL 21 1998	Kimura et al, FEBS Letters, Vol. 250(2), pages 377-380, 1989.
TRADEMARTIN	Wahl et al, The Journal of Nuclear Medicine, Vol. 24, pages 316-325, 1983.
	Ruf et al, Clincal Chemistry, Vol. 34(11), pages 2231-2234, 1988.
	Kaufman et al, Molecular and Cellular Endocrinology,
	Vol. 78, pages 107-114, 1991.
	Burgess et al, The Journal of Cell Biology, Vol. 111, pages 2129-2138, 1990.
	Tao et al, <i>The Journal of Immunology</i> , Vol. 143(8), pages 2395-2601, 1989.
	Gillies et al, <i>Hum. Antibod. Hybridomas</i> , Vol. 1(1), pages 47-54, 1990.
-	Lazar et al, Molecular and Cellular Biology, Vol. 8(3), pages 1247-1252, 1988.
	Kendler et al, Clinical Endocrinology, Vol. 33, pages 751-760, 1990.
	Foti et al, Biochemical and Biophysical Research Communications,  Vol. 168(1), pages 281-287, 1990.
EXAMINER	DATE CONSIDERED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO. 102105.151CIPDIV3 APPLICANT

SERIAL NO. 08/482,402

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Basil Rapoport

(Use several sheets if necessary) (37 CRF 1.98(b))

FILING DATE June 7, 1995 GROUP 1806

#### OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication

	<u> </u>	nen Do	COMENTS (including Addior, Title, Date, Nelevant pages, Place of Publication)
			Kaufman et al, Journal of Clinical Endocrinology and Metabolism,
~\\P\&	= 72	W	Vol. 70(3), pages 724-728, 1990.
211	998		Magnusson et al, <i>FEBS Letters,</i> Vol. 208(2), pages 391-396, 1986.
3. 3.			
TRADE	MAR		Magnusson et al, The Journal of Biological Chemistry,
OIPE			Vol. 262(29), pages 13885-13888, 1987.
JUL 21 T	C 822		Libert et al, The EMBO Journal, Vol. 6(13), pages 4193-4196, 1987.
JUL 21.			
TE TRADE	MARKE		Magnusson et al, Molecular Endocrinology, Vol. 1(11), pages 856-861, 1987.
	i		
			Kimura et al, <i>Proc. Natl. Acad, Sci. USA</i> , Vol. 84, pages 5555-5559, 1987.
			Adler et al, Analytical Biochemistry, Vol. 148, pages 320-327 (1985).
			Bogner et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 59(4), pages 734-738, 1984.
		i	Clark et al, Enzyme-Immunoassay, Chapter 8, pages 167-170 and 191-194.
		,	
			Czarnocka et al, <i>FEBS Letters</i> , Vol. 190(1), pages 147-152, 1985.
		,	
	١	/	
	EXAMINE	ER	DATE CONSIDERED 3 /4/25
			1////

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

,

# FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CRF 1.98(b)) ATTY DOCKET NO. 102105.151CIPDIV3 SERIAL NO. 08/482,402 APPLICANT Basil Rapoport FILING DATE June 7, 1995 1806

#### OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

			Doble et al, Immunology, Vol. 64, pages 23-29, 1988.
	Su		
IPE			Elisei et al, Autoimmunity, Vol. 8, pages 65-70, 1990.
2 1 1997 W			
7 1998 C			Hirayu et al, Journal of Clinical Endocrinology and Metabolism,
OF ARK OFF			Vol. 64(3), pages 578-584, 1987.
-			Finke et al, Progress in Thyroid Research, pages 437-439, 1991.
<del></del>			
		Ш	Finke et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 73(4), pages 919-921, 1991.
		Ц	Jansson et al, Clin exp. Immunol., Vol. 63, pages 80-86, 1986.
		$\perp$	
			Kaufman et al, The Journal of Clinical Investigation,
			Vol. 84, pages 394-403, 1989.
			Kohno et al, Clin exp. Immunol., Vol. 65, pages 534-541, 1986.
			Kohno et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 67(5), pages 899-907, 1988.
<u></u>			
	Π,		
	$ \Psi $		
EXAMINER		J.	DATE CONSIDERED 9/4/98
		VI !	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CRF 1.98(b))

ATTY DOCKET NO. 102105.151CIPDIV3

APPLICANT

Basil Rapoport

FILING DATE
June 7, 1995

1806

#### OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

——————————————————————————————————————	EN DO		MENTS (including Author, Title, Date, Relevant pages, Place of Publication)
IPA			Libert et al, Journal of Clinical Endocrinology and Metabolism,
]	Su		Vol. 73(4), pages 857-860, 1991.
2 1 1998 &			Mariotti et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 65(5), pages 987-993, 1987.
ADEMARKOT:			Nilsson et al, Molecular and Cellular Endocrinology,
			Vol. 53, pages 177-186, 1987.
			Ohtaki et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 63(3), pages 570-576, 1986.
			Portmann et al, Journal of Clinical Endocrinology and Metabolism,
			Vol. 61(5), pages 1001-1003, 1985.
			Portmann et al, Journal of Clinical Investigation,
	1		Vol. 81, pages 1217-1224, 1988.
			Ruf et al, <i>Endocrinology</i> , Vol. 125(3), pages 1211-1218, 1989.
			Sanger et al, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 74(12), pages 5463-5467, 1977.
		П	Van Regenmortel et al, Immunology Letters, Vol. 17, pages 95-108, 1988.
		П	
			Yokoyama et al, Journal of Clinical Endocrinology and Metabolism,
		П	Vol. 68(4), pages 766-773, 1989.
	. /	П	
_			
EXAMINER		/	DATE CONSIDERED
		<u>]</u>	9/1/30

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.
(Modified)	PATENT AND TRADEMARK OFFICE	102105,151CIPDIV3	08/482,402
	ENFORMATION DISCLOSURE STATEMENT BY APPLICANT		
(Use	several sheets If necessary)	FILING DATE	GROUP
(37 CRF 1.98(b))		June 7, 1995	1806

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant pages, Place of Publication)

		Zanelli et al, Clin exp. Immunol., Vol. 87, pages 80-86, 1992.
E À	54	
	,	Magnusson et al, European Thyroid Meeting, July 1986.
M 2, 8		
M. 2. ESS.		Magnusson et al, American Thyroid Association Meeting, September 1987,
• • • • • • • • • • • • • • • • • • •		Kimura et al, American Thyroid Assoication Meeting, September 1987.
<del></del>		Magnusson et al, European Thyroid Meeting, September 1988.
		Dinsart et al, European Thyroid Meeting, September 1988.
		Hata et al, Biochemical and Biophysical Research Communications,
		Vol. 164(3), pages 1268-1273, 1989.
		Nagayama et al, Journal of Clinical Endocrinology and Metabolism,
		Vol. 71(2), pages 384-390, 1990.
		Hosoya et al, J. Biochem., Vol. 98(3), pages 637-648, 1985.
EXAMINI	<del></del> ER	DATE CONSIDERED 4/4/Q s/